BRAF Biomarkers
Erasca Begins Phase Ib/II Master Protocol Trial of ERAS-007 in Gastrointestinal Cancers
The company will initially study the ERK1/2 inhibitor in combination with other therapies in biomarker-defined advanced colorectal cancers.
Cedars-Sinai Researchers Hunt for Rx Options for RAF-Mutated Pancreatic Cancer in Real-World Data
Premium
After a retrospective analysis identified targeted treatment opportunities for this subset of patients, researchers began a Phase II trial of a MEK and BRAF inhibitor.
Instil Bio to Begin Phase II Trial of TIL Therapy for Advanced Melanoma
The firm expects data from the trial to support regulatory filings for its autologous tumor-infiltrating lymphocyte treatment in the US and EU.
Pfizer, Erasca Partner to Study Three-Drug Combo in BRAF V600E-Mutated Metastatic Colon Cancer
The firms will assess the activity of Erasca's ERK1/2 inhibitor ERAS-007, Pfizer's BRAF inhibitor Braftovi, and Eli Lilly's EGFR inhibitor Erbitux in a Phase Ib/II trial.
Long-term NCI Follow-up of TIL Therapy for Melanoma Sheds Light on Potential Frontline Benefit
Researchers evaluated metastatic melanoma patients treated with autologous TILs over two decades and found that prior treatment impacted survival benefit.